Iovance Biotherapeutics, Inc (IOVA) insider trading
Every open-market stock purchase and sale by Iovance Biotherapeutics, Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.
Insider activity at a glance
- No open-market insider trades in the last 12 months.
- Last insider buy: Daniel Gordon Kirby (C-suite exec), $55.2K, 17 months ago.
Last 12 months: insiders bought $0 (0 buys) and sold $0 (0 sales). Last close $14.14 on Oct 22, 2026.
Recent IOVA insider trades
| Date | Insider | Trade | Value |
|---|---|---|---|
| Sep 30, 2026 | Noah Berkowitz (C-suite exec) | Bought (not open market) | — |
| Sep 30, 2026 | Noah Berkowitz (C-suite exec) | Bought (not open market) | — |
| Sep 8, 2026 | Frederick G Vogt (CEO) | Sold (not open market) | $57.8K |
| Sep 8, 2026 | Raj K. Puri (C-suite exec) | Sold (not open market) | $39K |
| Sep 8, 2026 | Igor Bilinsky (COO) | Sold (not open market) | $34.6K |
| Sep 8, 2026 | Igor Bilinsky (COO) | Bought (not open market) | — |
| Sep 8, 2026 | Frederick G Vogt (CEO) | Bought (not open market) | — |
| Sep 8, 2026 | Igor Bilinsky (COO) | Bought (not open market) | — |
| Sep 8, 2026 | Raj K. Puri (C-suite exec) | Bought (not open market) | — |
| Sep 8, 2026 | Raj K. Puri (C-suite exec) | Bought (not open market) | — |
| Sep 8, 2026 | Frederick G Vogt (CEO) | Bought (not open market) | — |
| Sep 1, 2026 | Frederick G Vogt (CEO) | Sold (not open market) | $147K |
| Sep 1, 2026 | Igor Bilinsky (COO) | Sold (not open market) | $37K |
| Sep 1, 2026 | Raj K. Puri (C-suite exec) | Sold (not open market) | $20.8K |
| Sep 1, 2026 | Igor Bilinsky (COO) | Bought (not open market) | — |
| Sep 1, 2026 | Igor Bilinsky (COO) | Bought (not open market) | — |
| Sep 1, 2026 | Frederick G Vogt (CEO) | Bought (not open market) | — |
| Sep 1, 2026 | Frederick G Vogt (CEO) | Bought (not open market) | — |
| Sep 1, 2026 | Raj K. Puri (C-suite exec) | Bought (not open market) | — |
| Sep 1, 2026 | Raj K. Puri (C-suite exec) | Bought (not open market) | — |
| Aug 10, 2026 | Daniel Gordon Kirby (C-suite exec) | Sold (not open market) | $15.6K |
| Aug 10, 2026 | Daniel Gordon Kirby (C-suite exec) | Bought (not open market) | — |
| Aug 10, 2026 | Daniel Gordon Kirby (C-suite exec) | Bought (not open market) | — |
| Aug 6, 2026 | Corleen M. Roche (CFO) | Sold (not open market) | $132K |
| Aug 6, 2026 | Corleen M. Roche (CFO) | Bought (not open market) | — |
Who's trading IOVA
- Noah Berkowitz, C-suite exec: other filings, last Sep 30, 2026
- Igor Bilinsky, COO: other filings, last Sep 8, 2026
- Frederick G Vogt, CEO: other filings, last Sep 8, 2026
- Raj K. Puri, C-suite exec: other filings, last Sep 8, 2026
- Daniel Gordon Kirby, C-suite exec: other filings, last Aug 10, 2026
- Corleen M. Roche, CFO: other filings, last Aug 6, 2026
- Michael Weiser, Director: other filings, last Jun 16, 2026
- Ryan D Maynard, Director: other filings, last Jun 16, 2026
- Iain D. Dukes, Director: other filings, last Jun 16, 2026
- Athena Countouriotis, Director: other filings, last Jun 16, 2026
- Finckenstein Friedrich Graf, C-suite exec: other filings, last Jun 5, 2026
Get free alerts when an insider at Iovance Biotherapeutics, Inc files a new trade →